Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianpi Huatan Tongfu is a Traditional Chinese Medicine (TCM) herbal formulation, typically administered as a granule, used for the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Its name reflects its therapeutic principles in TCM: strengthening the spleen (Jianpi), resolving phlegm (Huatan), and unblocking the bowels (Tongfu). Clinically, it has been shown to alleviate inflammatory responses by reducing levels of C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-α (TNF-α). Additionally, the formulation appears to modulate the gut-lung axis by altering the composition of intestinal flora, specifically increasing the abundance of Firmicutes while decreasing Bacteroidetes and Verrucomicrobia in patients with AECOPD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jianpi Huatan Tongfu.